Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific announced the FDA approval of expanded labeling for its pulsed field ablation system which now includes ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of ...

Memorial Health System’s Department of Cardiology has announced the successful launch of the FARAPULSE Pulsed Field Ablation ...

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston ...